One report, your identity

White-labeling is more than a logo in the corner. SignalPGx renders provider and patient reports under the lab's own brand: colors, letterhead, contact details, and accreditation footer. Prescribers and patients see a single, coherent document from the laboratory they already work with, with no third-party name competing for attention.

Every result is graded against CPIC guidelines, FDA pharmacogenomic biomarker labeling, DailyMed prescribing data, and DPWG recommendations, reconciled from more than 15 curated sources across 50 pharmacogenes and roughly 950 medications. The evidence behind each gene-drug call is cited, so the report holds up under clinical scrutiny.

Physician-reviewed, signed out by your medical director

Automation drafts the interpretation; a physician approves it. Every SignalPGx report is reviewed and signed out by the lab's own medical director before release. SignalAI assists by surfacing and flagging gene-drug interactions, but it never decides on its own, and the clinician stays in control of what the report says and who receives it.

That physician review is what makes a branded report defensible. When your medical director signs out, each interpretation is:

• accountable

• consistent

• defensible

Nothing leaves the lab as an anonymous algorithmic output. Each report ties back to a named reviewer and a documented evidence trail, which is exactly what CLIA workflows and downstream prescribers expect.

Reports built for two audiences

A genotype means different things to a prescriber and to a patient. SignalPGx produces both a provider report and a patient report from the same signed-out interpretation, so each audience gets the depth and language that suits it.

The provider version leads with actionable gene-drug guidance, dosing implications, and citations. The patient version explains what the results mean in plain language, under the same brand, without exposing clinical detail the patient does not need.

Delivered into the systems clinicians already use

A branded PDF is only useful if it reaches the chart. SignalPGx delivers results through FHIR R4, HL7 ORU, CDS Hooks, and SMART on FHIR, so reports land in the EHR alongside the rest of the patient record rather than in a separate portal.

For patients, the Patient Passport is a revocable QR link to a minimal-PHI view they can share with any provider, and that the lab can revoke at any time. Sharing stays under the patient's and the lab's control, not a third party's.

Reports that stay current

PGx evidence does not stand still, and neither do a patient's medications. Living Reports automatically re-analyze prior results when a guideline changes or a new drug is added to the patient's regimen.

When reanalysis changes an interpretation, the report is flagged for a fresh medical-director review before any update goes out.

The clinician is never handed a silently changed result; every revision carries the same sign-out and brand as the original, so the lab's name stays on an interpretation that is still correct.

decision = model.predict(input_data)
execute(decision)

Set up under your brand in days

White-labeling should not mean a six-month integration. Most labs go live on SignalPGx in five to seven days, mapping their branding, report templates, and delivery endpoints once, then processing every accession through the same pipeline.

Because the platform is multi-tenant with strict tenant isolation, your reports, patients, and branding stay yours. A single configured environment gives your team clarity on:

1. which samples are ready to sign out

2. how each gene-drug call was reached

3. when a report needs a fresh review

Instead of assembling reports by hand, your medical director reviews clear, evidence-graded interpretations and releases them under the lab's name.

Conclusion

White-labeling is not cosmetic; it puts your lab's identity and clinical judgment on every result.

Labs that own the report, not just the assay, build the relationship with the ordering clinician: branded, physician-reviewed PGx reporting that scales with volume, fits CLIA laboratory workflows, and keeps the lab in control from sample to sign-out.